Member Info for ogm4

1 hr

#ImmuPharma announces a significant milestone in evidencing the unique mechanism of action (“MOA”) of its #P140 autoimmune technology platform.

https://bit.ly/3DpEEZS

https://x.com/ImmuPharma/status/1900083478156153145

A truly compelling story unfolding here by the looks of it

I must say I am quite pleased now with the regular news flow coming from the company since the start of this year. Both RNS's and interviews.

Another interview out next week then?

"results are extremely compelling"

buying more today for sure ;-)

Buckle up today folks!!!

Something big in the making here!....

WOW!!!!!!!!!....

Commenting on this announcement, Tim McCarthy, CEO of ImmuPharma, said:"These stunning results clearly demonstrate the unique MOA of P140 and this data adds significantly to our ongoing discussions with potential partners and our objective to secure the optimum deal(s) for our shareholders."

.

If Immupharma was currently already rated at 80 or 100 Million GBP market cap or above it would be different...

but it is not, it is only sitting at 13 million GBP mc currently including also a few million in cash. Let alone all the prorietary knowledge and patents in house.

"This is the year it is all coming together"

"2025 will be transformational"

Here is an example of a previous deal in autoimmune disease market where GSK agreed to pay $300 million upfront payment. Just an example of the potential market opportunities out there...

https://www.paulweiss.com/practices/transactional/mergers-acquisitions/news/gsk-agrees-to-acquire-autoimmune-disease-treatment-from-chimagen-biosciences?id=55213

The dilution was relatively small, not like other dilutions we've seen in the past on AIM like 20-30% range or even above.

Remember they did not even had to raise as there was still sufficient money in the bank. Because of a few shareholders preference they now have an even stronger negotiation position at the table. Plenty of cash until end of next year.

Close friend of mine his wife and daughter are both suffering from a specific autoimmune disease. It would be great if Immupharma could further develop the P140 platform and release fit-for-purpose personalised medicines which could help all these patients worldwide. Come on Tim and team, let's make a move!...

600,000 buy at 3.32p this afternoon it looks like

Tick up indeed

Absolute radio silence at the moment

Big market out there...

The future of immunology

Written by Barbara Brody

March 3, 2025

https://www.jnj.com/innovation/the-future-of-immunology

Indeed, IMM has now even more cash in the bank at least until the end of 2026, so they are in a stronger negotiation position at the table. JV's, collaboration, takeovers but also issuing license offtake deals.

Some studies estimating 3-12% global increase annually.

Let's show some groundbreaking deals Immupharma!

GUEST BLOG: A MAJOR HEALTH CRISIS: THE ALARMING RISE OF AUTOIMMUNE DISEASE

March 28, 2024

By Molly Murray, President and CEO, Autoimmune Association

https://nationalhealthcouncil.org/blog/a-major-health-crisis-the-alarming-rise-of-autoimmune-disease/